2025 年 11 月 24 日,上海毕得医药科技股份有限公司第二届董事会第二十七 次会议在公司会议室召开。应到董事 6 人，实到董事 6 人。本次会议的召开符合 《中华人民共和国公司法》、相关法律法规及公司章程的规定。 本次会议形成如下决议: 一、审议通过《关于补选公司第二届董事会非独立董事的议案》 同意 6 票,反对 0 票, 弃权 0 票。 本议案尚需提交公司股东会审议。 二、审议通过《关于召开公司 2025 年第五次临时股东会的议案》 同意 6 票,反对 0 票, 弃权 0 票。 特此决议。 (以下无正文,为签署页) 上海毕得医药科技股份有限公司 第二届董事会第二十七次会议 会议决议 1 w w 许丽姣: 2025 年 11 月 24 日 （本页无正文，为《上海毕得医药科技股份有限公司第二届董事会第二十七次会 议决议》之签署页) （本页无正文，为《上海毕得医药科技股份有限公司第二届董事会第二十七次会 议决议》之签署页） 戴岚： 2025 年 11 月 24 日 （本页无正文，为《上海毕得医药科技股份有限公司第二届董事会第二十七次会 议决议》之签署页） 尚卓婷： 2025 年 11 月 24 日 （本页 ...

Core Viewpoint - Bid Pharma's stock price has shown significant growth this year, with a year-to-date increase of 54.24%, indicating strong market performance and investor interest [1][2]. Company Overview - Bid Pharma, established on April 27, 2007, and listed on October 11, 2022, is located in Yangpu District, Shanghai. The company focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1]. - The company's main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1]. Financial Performance - For the period from January to September 2025, Bid Pharma achieved operating revenue of 979 million yuan, representing a year-on-year growth of 20.67%. The net profit attributable to the parent company was 120 million yuan, reflecting a year-on-year increase of 42.79% [2]. - Since its A-share listing, Bid Pharma has distributed a total of 258 million yuan in dividends [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Bid Pharma was 3,493, a decrease of 7.64% from the previous period. The average number of circulating shares per person increased by 8.27% to 12,377 shares [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and others, with several new entrants and some exiting the list [3].

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]

Group 1 - The core viewpoint of the news is that Bid Pharma has seen a stock price increase of 5.01%, reaching 75.90 CNY per share, with a total market capitalization of 6.898 billion CNY [1] - Bid Pharma focuses on the front end of the new drug research and development industry chain, providing innovative drug molecular building blocks and scientific reagents [1] - The main business revenue composition includes: 43.26% from molecular building block heterocyclic compounds, 23.32% from molecular building block aromatic compounds, 16.36% from molecular building block aliphatic compounds, 10.57% from catalysts and ligands, and 6.49% from life science reagents [1] Group 2 - The Guotou Ruijin Healthcare Mixed A Fund holds 53,200 shares of Bid Pharma, accounting for 2.84% of the fund's net value, ranking as the ninth largest holding [2] - The fund has achieved a year-to-date return of 32.49%, ranking 2279 out of 8136 in its category [2] - The fund manager, Liu Zexu, has a tenure of 2 years and 71 days, with the best fund return during this period being 31.19% [3]

证券代码：688073 证券简称：毕得医药 公告编号：2025-085 上海毕得医药科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 投资者可于 2025 年 11 月 20 日（星期四）至 11 月 26 日（星期三） 16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过 公司邮箱 ir@bidepharmatech.com 进行提问。公司将在说明会上对投 资者普遍关注的问题进行回答。 上海毕得医药科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 30 日发布公司 2025 年第三季度报告，为便于广大投资者更 全面深入地了解公司 2025 年第三季度经营成果、财务状况，公司计 划于 2025 年 11 月 27 日（星期四）14:00-15:00 举行 2025 年第三季度 业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 本次投资者说明会以网络互动形式召开，公司将针对 2025 年第 会议召开时间：2025 ...

Core Viewpoint - The announcement details a significant change in shareholder equity for Shanghai Bid Medical Technology Co., Ltd., indicating a reduction in shareholding by certain stakeholders, which has triggered a disclosure obligation due to the 1% threshold being crossed [1][4]. Group 1: Shareholder Information - The information disclosure obligors include Zhoushan Landan Enterprise Management Partnership (Limited Partnership), Zhoushan Xinxin Enterprise Management Partnership (Limited Partnership), and Wu Bo, who are identified as acting in concert [3][4]. - The total shareholding of the obligors decreased from 10,110,686 shares (11.12%) to 9,571,125 shares (10.53%) following the reduction of 539,561 shares, which represents 0.59% of the total share capital [4]. Group 2: Equity Change Details - The equity change occurred on November 13, 2025, when Landan Management executed a block trade to reduce its holdings [4]. - This reduction is part of a previously disclosed share reduction plan and does not trigger a mandatory tender offer [5]. Group 3: Impact and Compliance - The equity change is not expected to significantly impact the company's governance structure or ongoing operations, nor will it alter the controlling shareholder or actual controller [5]. - The reduction plan is still ongoing, and the company will ensure compliance with relevant regulations and timely disclosure of information to investors [6].

证券代码：688073 证券简称：毕得医药 公告编号：2025-084 上海毕得医药科技股份有限公司 关于股东权益变动触及 1%刻度的提示性公告 股东舟山兰旦企业管理合伙企业(有限合伙)（原宁波兰旦企业管理合伙企业(有限 合伙)）、舟山欣曦企业管理合伙企业(有限合伙)、吴波保证向本公司提供的信息真实、 准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司董事会及全体董事保证公告内容与信息披露义务人提供的信息一致。 一、 信息披露义务人及其一致行动人的基本信息 1.身份类别 | | □控股股东/实际控制人及其一致行动人 ☑其他 5%以上大股东及其一致行动人 | | --- | --- | | 投资者及其一致行动人的身份 | □合并口径第一大股东及其一致行动人（仅适用 | | | 于无控股股东、实际控制人） | | | □其他______________（请注明） | 注：舟山欣曦企业管理合伙企业（有限合伙）、舟山兰旦企业管理合伙企业(有 限合伙)、吴波为一致行动人。 二、 权益变动触及 1%刻度的基本情况 2025 年 11 月 13 日，上海毕得医药科技股份有限公司（以下简称"公司"） 收到公司股东舟山兰 ...

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction by Lan Dan Management through block trading, impacting the company's total shareholding structure [1] Group 1 - On November 13, 2025, Lan Dan Management reduced its holdings by a total of 539,600 shares, representing 0.59% of the company's total share capital [1] - Following this equity change, the combined shareholdings of Lan Dan Management, Xin Xi Management, and Wu Bo decreased from 10.11 million shares to 9.57 million shares [1] - The overall shareholding ratio of these entities fell from 11.12% to 10.53%, marking a change that touches the 1% threshold [1]

Core Viewpoint - Bid Pharma (688073.SH) announced a share reduction by Lan Dan Management through block trading, impacting the company's total shareholding structure [1] Group 1 - On November 13, 2025, Lan Dan Management reduced its holdings by a total of 539,600 shares, representing 0.59% of the company's total share capital [1] - Following this equity change, the combined shareholdings of Lan Dan Management, Xin Xi Management, and Wu Bo decreased from 10.11 million shares to 9.57 million shares [1] - The overall shareholding ratio of these entities fell from 11.12% to 10.53%, marking a change that touches the 1% threshold [1]

Market Overview - The medical services sector declined by 0.47% on November 14, with the digital human sector leading the drop [1] - The Shanghai Composite Index closed at 3990.49, down 0.97%, while the Shenzhen Component Index closed at 13216.03, down 1.93% [1] Stock Performance - Notable declines in individual stocks include: - Digital Human: closed at 17.28, down 4.85% with a trading volume of 80,400 shares and a turnover of 1.411 million [1] - Haoyuan Pharmaceutical: closed at 77.20, down 3.54% with a trading volume of 30,800 shares and a turnover of 2.4212 million [1] - Yinos: closed at 48.69, down 2.62% with a trading volume of 14,300 shares and a turnover of 7132.217 [1] - Other notable declines include Taige Pharmaceutical, MediX, and WuXi AppTec, all showing declines between 1.28% and 2.08% [1] Capital Flow - The medical services sector experienced a net outflow of 238 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [3] - Notable capital flows for specific stocks include: - Ruizhi Pharmaceutical: net inflow of 38.93 million yuan from institutional investors, but net outflows from retail and speculative investors [3] - Chengda Pharmaceutical: net inflow of 37.96 million yuan from institutional investors, with significant outflows from speculative investors [3] - Other stocks like Sanbo Brain Science and Jinyu Medical also showed varying net inflows and outflows among different investor types [3]